Endomedix has developed a platform technology with 4 major potential applications. The Company is developing its first product, an absorbable sugrical hemostat for brain and spinal surgery. The core development for this product has been completed. The hemostat does not swell in use and has the most rapid action of any absorbable hemostat. The hemostat has 5 mechanisms of action, 4 of which are subject to patent application. The technology is based on polysaccharides and is protected by 8 issued patents and two pending patent applications. The starting materials of the product have a longhistory of use in FDA-regulated products.,Endomedix has developed a platform technology with 4 major potential applications. The Company is developing its first product, an absorbable sugrical hemostat for brain and spinal surgery. The core development for this product has been completed. The hemostat does not swell in use and has the most rapid action of any absorbable hemostat. The hemostat has 5 mechanisms of action, 4 of which are subject to patent application. The technology is based on polysaccharides and is protected by 8 issued patents and two pending patent applications. The starting materials of the product have a longhistory of use in FDA-regulated products.